DexCom Faces Legal Deadline Amid Investor Lawsuit Over Misleading Device Claims

2025-12-07 companies

New York, Saturday, 6 December 2025.
DexCom investors must act by December 26, 2025, to join a class action lawsuit alleging misleading statements about G6 and G7 devices, impacting reliability and safety, leading to significant losses.

Background of the Lawsuit

The class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) arises from allegations that the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring (CGM) systems. These changes allegedly compromised the devices’ reliability and posed health risks to users who depend on accurate glucose readings. The lawsuit claims DexCom’s public statements about the devices’ enhancements and reliability were materially false and misleading at all relevant times [1][2].

Timeline and Legal Implications

Investors in DexCom securities who purchased between January 8, 2024, and September 17, 2025, are encouraged to join the class action by the lead plaintiff deadline of December 26, 2025. This legal action follows significant financial losses attributed to DexCom’s alleged failure to disclose material design changes that lacked FDA approval, leading to heightened regulatory scrutiny and adverse market reactions [1][3].

Financial Impact and Market Reaction

DexCom’s stock has experienced significant volatility due to these allegations. Notably, after announcing disappointing Q2 2024 results, the company’s stock price fell by $43.85, representing a 40.66% decline, which was compounded by further declines following other adverse disclosures, including an FDA Warning Letter in March 2025 [4][5].

Investor Actions and Legal Counsel

Investors who suffered losses exceeding $100,000 are advised to seek legal representation to participate in the lawsuit. Law firms such as Rosen Law Firm and Kessler Topaz Meltzer & Check, LLP, are at the forefront of representing aggrieved investors. Potential lead plaintiffs must act promptly before the December 26, 2025, deadline to maximize their chances of recovery [1][3][6].

Sources

investor rights DexCom Inc